<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788229</url>
  </required_header>
  <id_info>
    <org_study_id>dhpat02</org_study_id>
    <nct_id>NCT00788229</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Safety of DHP-101, DHP-300, DHP-500 in Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dhp Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dhp Korea Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether artificial tears are safe and effective in&#xD;
      the treatment of Dry Eye Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Break Up Time (TBUT)</measure>
    <time_frame>12weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluorescein staining, schirmer test, OSDI, VAS</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>1. Study Drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Study Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Study Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT01</intervention_name>
    <description>eye drop for 12 weeks</description>
    <arm_group_label>1. Study Drugs</arm_group_label>
    <other_name>DHP-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT02</intervention_name>
    <description>eye drop for 12 weeks</description>
    <arm_group_label>2. Study Drug</arm_group_label>
    <other_name>DHP-300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT03</intervention_name>
    <description>eye drop for 12 weeks</description>
    <arm_group_label>3. Study Drug</arm_group_label>
    <other_name>DHP-500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT04</intervention_name>
    <description>eye drop for 12 weeks</description>
    <arm_group_label>4. Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults aged 18 years and over.&#xD;
&#xD;
          -  Subjects should diagnosed as dry eye syndrome in both eyes or one eye,&#xD;
             keratoconjunctivitis sicca (KCS), or should have at least a 3-month history diagnosed&#xD;
             as dry eye syndrome due to Sjögren syndrome.&#xD;
&#xD;
          -  Subjects must agree to discontinue all artificial tears from Screening for 2 weeks&#xD;
&#xD;
          -  Subjects must discontinue lens wear one week before Screening and agree not to wear&#xD;
             contact lenses during the entire study.&#xD;
&#xD;
          -  Subjects who have taken Restasis® are eligible for inclusion if they have not used&#xD;
             Restasis® during the 4 weeks prior to Screening&#xD;
&#xD;
          -  Subjects must provide signed informed consent prior to participation in any&#xD;
             study-related procedures&#xD;
&#xD;
          -  Subjects who dose not Participate in same clinical trial within 6 month prior to&#xD;
             Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Females of childbearing potential who are not using systemic contraception,are not&#xD;
             postmenopausal (≥ 1 year), or are not surgically sterilized.&#xD;
&#xD;
          -  Ocular surgery (of any type, including laser surgery) or ocular trauma within the 4&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  Any active inflammation of the eye not due to KCS&#xD;
&#xD;
          -  Other diseases or characteristics judged by the investigator to be incompatible with&#xD;
             the assessments needed in this study or with reliable instillation of the study&#xD;
             medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hungwon Tchah,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul asan medical center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <state>388-1 Pungnap-2dong, Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>April 1, 2010</last_update_submitted>
  <last_update_submitted_qc>April 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Donghwa Han / The director of Laboratory</name_title>
    <organization>Dhp Korea Co., Ltd.</organization>
  </responsible_party>
  <keyword>Dry Eye Syndromes</keyword>
  <keyword>Keratoconjunctivitis Sicca</keyword>
  <keyword>artificial tears</keyword>
  <keyword>carboxymethylcellulose sodium</keyword>
  <keyword>sodium hyaluronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

